10/23/2013

The FDA and the European Medicines Agency have granted orphan-drug status to Ganymed's IMAB362 as a treatment for cancer of the pancreas. The monoclonal antibody drug also is under development for gastric and gastroesophageal cancer.

Full Story:
PharmaTimes (U.K.)

Related Summaries